Wockhardt insulin glargine
Insulin glargine biosimilar developed by Wockhardt. Reference product Lantus.
About Wockhardt insulin glargine
Wockhardt received the first insulin glargine permission in India, in February 2007, and one of the first anywhere in the world. The product was permitted in vials, cartridges and a pen, in both the international strength and the 40 units per mL strength still used in India.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Wockhardt insulin glargine holds an approval, these are the other insulin glargine biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 9 | Biocon Biologics (Semglee), Cipla (Cipla insulin glargine), Eli Lilly (Rezvoglar / Abasaglar), Eris Lifesciences (Eris insulin glargine), Genesys Biologics (Genesys insulin glargine), LG Chem (LG Life Sciences insulin glargine), Lupin (Lupin insulin glargine), M.J. Biopharm (M.J. Biopharm insulin glargine), Regenix (Regenix insulin glargine) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Wockhardt: Wockhardt epoetin, Wockhardt pegfilgrastim.
Chronology
- CDSCOFeb 2007CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning insulin glargine biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant